Refining a vaccine to prevent Type 1
Less than a year to run
London
Professor Mark Peakman
King’s College
£217,182 Clinical Training Fellowship
Mechanisms of action of peptide immunotherapy for Type 1 diabetes: characterising T cells induced or modified by proinsulin C19-A3.
May 2011 - May 2014
Project Summary
Researchers led by Professor Mark Peakman at King’s College London are currently conducting a trial of a vaccine which they hope will trigger an immune response to protect against Type 1 diabetes. In this project Clinical Research Training Fellow, Dr Yuk-Fun Liu, aims to determine exactly how this vaccine works, in order to help develop and refine it.
Professor Mark Peakman talks about his work on Type 1 diabetes in the
King's College research labs at Guy's Hospital